Over the past several years modern medicine has made great strides in the fight against Multiple Sclerosis. In just the past five years three new medications have been approved by the FDA to fight MS with amazing results. The strongest of these is Tysabri. Tysabri was approved after studies showed that it could cut...
Drugs
New MS Drug Shows Great Success Rate
A woman named Jennifer Garner was diagnosed with multiple sclerosis in 2004 after losing the sensation of feeling in the entire left side of her body. The drug Rebif provided relief for a short time until her illness progressed to a point at which Rebif could no longer work to combat the symptoms of...
Gilenya trial finishes with promising results for RRMS sufferers
After a two-year, randomized, control study of 2,000+ RRMS patients, drugmaker Novartis announced promising findings. Patients taking a once-daily oral dose of fingolimod saw a decrease of almost half in annual relapse rates of RRMS. This reduction in attacks resulted in patients with a better-functioning nervous system than the unmedicated control. In addition, the...
Improved walking with new drug
MS patients reported improved walking after taking extended release drug Ampyra (Nasdaq: ACOR). “People with MS often experience a progressive decline in their walking ability that can begin early in their disease course. However, in many cases patients and their healthcare providers do not discuss walking impairment until it is so severe that it...
Copaxone phase III trial concludes
Patient enrollment in an international Phase III trial for Teva’s popular MS drug, Copaxone. The are over 1,400 patients enrolled at 180 sites in the US, Europe, Central Eastern Europe and Israel. The phase is meant to evaluate the efficacy, safety and tolerability of 40mg COPAXONE (glatiramer acetate injection) administered three times a week compared to...
New Drug Targets MS Differently
Scientists at SCRIPPS have developed a new drug (SR1001). It stops MS by knocking out TH17, a type of white blood cell that malfunctions in patients with MS. Current treatments for autoimmunity suppress the patient’s entire immune system, leaving patients vulnerable to a range of adverse side effects. This drug targets only specific cell...
New Drug Could Slow Progression of MS
The new experimental oral multiple sclerosis (MS) drug laquinimod has reduced relapse rates, delayed disease progression, and was very safe and well tolerated by patients in a two-year study. The drug’s developer, Teva Pharmaceutical Industries announced details of the study, Monday at the 63rd Annual Meeting of the American Academy of Neurology in Hawaii....
FDA Approves New Multiple Sclerosis Pill
A new drug recently approved by the FDA will replace needles for many patients: Unlike current MS drugs, which are given by injections or infusion, the new drug, called Gilenya or fingolimod, comes in a capsule (pill) which is taken once a day. Immediately following the approval, many within the health sector noted that...
Tovaxin
Opexa Therapeutics, Inc. announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). This analysis evaluated patients with an annualized relapse rate of one or greater at study entry (ARR≥1). More than 83% of the Tovaxin-treated group (n=85) remained relapse free...
Inflammation and paralysis reversed with common blood pressure medication
Conventional blood pressure medication can treat inflammation in an animal model mimicking multiple sclerosis (MS). This discovery was made by Dr. Michael Platten, head consultant at the department of Neurooncology at Heidelberg University Hospital and head of the Helmholtz Experimental Neuroimmunology Junior Research Group on at the German Cancer Research Center and his team...
Recent Comments